https://www.selleckchem.com/pr....oducts/Abitrexate.ht
6% had lung metastases. Next-generation sequencing (NGS) was used in 36.6% of cases and polymerase chain reaction (PCR) in 16.6% of cases. KRAS mutations were present in 83.3% of patients and NRAS mutations in 16.6% of patients. Survival could be assessed in 10 patients and the median was 21.1 months (about 30% lower than the survival in the general mCRC population). Conclusion The results of this systematic review suggest the need to design a cohort study (either prospective or retrospective) to better characterize the patients with
Like
Comment
Share
